Overall Survival with Abemaciclib in Early Breast Cancer
{{output}}
Background: Adjuvant abemaciclib combined with endocrine therapy (ET) significantly improved invasive disease-free survival (IDFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-)... ...
